Sound Insights.

Noninvasix is expected to be the first company to non-invasively monitor central venous oxygenation, an indicator of the severity of sepsis and septic shock, enabling clinicians to diagnose and monitor the response to treatment of tissue hypoxia in real-time.

Noninvasix’s patented optoacoustic platform technology is the first solution designed to non-invasively and continuously measure central venous saturation.

Incorporating Noninvasix into the ICU workflow is expected to allow clinicians to more quickly and accurately diagnose their critically ill patients and tailor treatments to improve outcomes. Future patient care applications may include indications and settings where tissues hypoxia is present, such as fetal monitoring, neonatal care, traumatic brain injury, blood loss and anemia.
adult admissions from sepsis per yr
0 M
of all hospital mortality
0 %
avg. per patient cost to treat sepsis
$ 0 K
increase in costs from sepsis
0 %

Impact of Sepsis

Sepsis is a potentially life-threatening dysfunction that occurs when the body’s response to an infection damages its own tissues. When the infection-fighting processes turn on the body, they cause organs to function poorly and abnormally, and may progress to septic shock – a plunge in blood pressure that can lead to severe organ problems and death. Early treatment with antibiotics and IV fluids improves chances for survival.

An Unmet Need

Noninvasix’s mission is to solve the acute challenge of detecting and monitoring sepsis to significantly improve patient care, save lives and reduce healthcare costs. It is the only patient monitoring system designed to non-invasively monitor sepsis by detecting a key indicator of septic shock as early as possible so it can be treated to reduce complications and save lives.